3 minute read
Nov. 28, 2022

A Selective CDK2 Inhibitor from Incyte

compound 5g

oral CDK2 Inhibitor oral/IV PK observed in rats in-house HTS and scaffold hopping ACS Med. Chem. Lett. Incyte Research Institute, Wilmington, DE

twitterlinkedinprintemail